GemPharmatech (SH:688046) Zheng Quan Shi Bao Wang·2025-04-11 07:54Core Insights - The FDA has released a roadmap aimed at reducing animal testing in preclinical safety research by utilizing scientifically validated new methods such as organ-on-a-chip systems, computational modeling, and advanced in vitro testing [2] - The company's research and development strategy aligns with the FDA's initiative, focusing on developing various modified models to better simulate human biological characteristics, thereby enhancing the reliability and translational efficiency of drug development [2] Group 1 - The FDA's roadmap is expected to have a minimal impact on the company's operations, which are currently running smoothly and showing stable revenue growth compared to the previous year [3] - The company is actively monitoring external environmental changes to ensure steady business growth [3] - The company announced a new fundraising project for an "AI-driven organoid and animal disease model multimodal preclinical drug research platform," aiming to accelerate the implementation of new technologies [3] Group 2 - The company plans to develop various research modules, including an organoid in vitro drug screening platform and a disease-based animal model in vivo drug evaluation system, to meet downstream market demands [3] - The company emphasizes the diversity, effectiveness, and reliability of its animal model products and disease-based animal services, which are essential for drug research and validation [2]